Brief: Incannex Announces Positive Pre-IND Meeting with U.S. FDA for IHL-42X for Obstructive Sleep Apnoea
17/05/2022 13:10
May 17 (Reuters) - Incannex Healthcare Ltd IHL.AX :
* INCANNEX ANNOUNCES POSITIVE PRE-IND MEETING WITH U.S. FDA
FOR
IHL-42X FOR OBSTRUCTIVE SLEEP APNOEA
* INCANNEX HEALTHCARE LTD - FDA AGREED THAT INCANNEX DOES
NOT NEED
TO CONDUCT STUDIES IN ANIMALS
* INCANNEX HEALTHCARE LTD - COMPLETE CLINICAL STUDY REPORT
IS
ANTICIPATED TO BE RELEASED IN JUNE 2022
Source text for Eikon: ID:nPn8gnKLDa
Further company coverage: IHL.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Incannex Healthcare
See all newsBrief: Incannex Healthcare Says Computershare To Be Appointed As US Transfer Agent
Brief: Incannex Healthcare Says Federal Court Of Australia Approved Proposed Schemes Of Arrangement Between Incannex And Its Shareholders
Australia's Incannex up as shareholders in favour of US redomicile
Brief: Incannex Healthcare Will Prepare FDA Ind Application PSI-Gad
Brief: Review Of Ind Application For Ihl-42X By Us FDA Has Been Completed Clinical Trial For Patients With Obstructive Sleep Apnoea May Proceed